Results 151 to 160 of about 19,854 (197)

Lipid lowering in coronary artery disease - not just statins. [PDF]

Clin Med (Lond)
Han J, Masmanian E, Wang T, Chua TP.
europepmc   +1 more source

Enhanced liver-targeted delivery with ribofuranose-based GalNAc conjugates. [PDF]

Mol Ther Nucleic Acids
Pradeep SP, Ruchi R, Bahal R.
europepmc   +1 more source

Gene Therapy for Cardiovascular and Cerebrovascular Disease: Mechanisms, Translational Barriers, and the Road Ahead. [PDF]

Biomedicines
Liu Z, Liu R, Ying Y, Nie J.
europepmc   +1 more source

ANGPTL3, Apo CIII, Leptin and Triglycerides Are Elevated in Metastatic Prostate Cancer. [PDF]

Cancers (Basel)
Boulay G, Khodr M, Bergeron AC, Wong Chong É, Joncas FH, Castonguay C, Robitaille K, Hovington H, Fradet V, Bergeron A, Pouliot F, Blais J, Seidah NG, Calon F, Gangloff A.   +14 more
europepmc   +1 more source

Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer.

JAMA Netw Open
Lu CA, Jiang C, Wang AZ, Zhang T.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Clinical aspects of PCSK9

Atherosclerosis, 2011
Proprotein convertase subtilisin kexin type 9 (PCSK9) is a circulating protein that impairs LDL clearance by promoting the LDL receptor (LDLR) degradation. PCSK9 has emerged as a new pharmacological target for hypercholesterolemia, and different PCSK9 inhibitors are now evaluated in clinical trials.
Bertrand Cariou, Cedric Le May, Philippe Costet   +2 more
exaly   +4 more sources